Apyx Medical ( (APYX) ) has released its Q3 earnings. Here is a breakdown of the information Apyx Medical presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Apyx Medical Corporation is a surgical aesthetics company known for its innovative products like Renuvion and the AYON Body Contouring System, which are used in cosmetic and hospital surgical markets to provide controlled heat to tissue for desired results.
In its third-quarter 2025 earnings report, Apyx Medical announced a successful commercial launch of its AYON Body Contouring System in the U.S., with pre-orders surpassing expectations. The company also raised its total revenue guidance for the fiscal year 2025 to a range of $50.5 million to $52.5 million.
Key financial highlights include a total revenue increase to $12.9 million, driven by a 19% rise in Surgical Aesthetics revenue, while OEM revenue saw a decline. The company reported a net loss of $2.0 million, a significant improvement from the $4.7 million loss in the same period last year. Adjusted EBITDA loss also decreased substantially to $0.1 million.
Apyx Medical’s strategic focus on the AYON system, which integrates multiple functionalities for body contouring, is expected to drive future growth. The company has submitted a 510(k) for label expansion to include power liposuction, which, upon approval, could further enhance its market position.
Looking forward, Apyx Medical aims to accelerate the adoption of AYON and expand its user base, with anticipated demand bolstered by pending FDA clearance for new functionalities. The company remains optimistic about its growth prospects in the surgical aesthetics market.